Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05842993
Other study ID # QDU-HD-2023/1732
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2023
Est. completion date October 10, 2023

Study information

Verified date May 2023
Source Qingdao University
Contact Tongshang Ni, Ph.D
Phone +86 17354605382
Email neetongshang@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of hydrogen inhalation in type 2 diabetes patients.


Description:

The objective of the study is to evaluate the efficacy and safety of hydrogen inhalation compared with placebo in patients with type 2 diabetes mellitus after 12-week treatment in a randomized, double-blind, placebo-controlled design.


Recruitment information / eligibility

Status Recruiting
Enrollment 96
Est. completion date October 10, 2023
Est. primary completion date October 10, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Aged 18-75 years old and gender of both sex; 2. Body mass index 18.5kg/m2 to 40 kg/m2; 3. Diagnosed as type 2 diabetes according to the diagnostic criteria of type 2 diabetes established by WHO in 1999; 4. Patients with type 2 diabetes whose blood glucose is not well controlled after diet control and exercise therapy for more than 3 months; 5. HbA1c 7% to 10%, and fasting venous plasma glucose = 15 mmol/L; 6. Be able to understand the procedures and methods of this clinical study, voluntarily participate in and sign the informed consent. Exclusion Criteria: 1. Type 1 diabetes, gestational diabetes, or other specific types of diabetes; 2. Screening for having received anti-diabetic drug therapy within 3 months or receiving continuous anti-diabetic drug therapy at any time before screening for more than 3 months; 3. History of diabetic ketoacidosis, diabetic hyperglycemic hyperosmolar syndrome, lactic acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic nephropathy and diabetic neuropathy; 4. Hyperlipidemia patients with irregular or unstable dose of lipid-lowering drugs 5. Chronic gastrointestinal disorders with obvious digestive and absorption disorders, as well as other endocrine diseases, such as hyperthyroidism, hypercortisolism, acromegaly, etc.; 6. Patients with diseases that may worsen due to intestinal flatulence (such as Roemheld syndrome, severe hernia, intestinal obstruction, intestinal surgery and intestinal ulcers); 7. Had transient ischemic attack, cerebrovascular accident or unstable angina in the past 6 months; History of myocardial infarction or had conducted coronary angioplasty or coronary artery bypass graft surgery; Heart failure (NYHA classification Stage III or IV), or left ventricular hypertrophy indicated by ECG; 8. Subjects (taking or not taking antihypertensive drugs) had poor blood pressure control (SBP = 160mmhg, or DBP = 100mmhg); 9. liver disease, ALT or AST > 2 ULN, or TBIL > 2 ULN, and the diagnosis was confirmed within one week; 10. Patients with renal function impairment (Cr > 1 ULN or Ccr < 60ml / min) and confirmed by reexamination within one week; 11. Had malignancy in the past 5 years, not including basal cell carcinoma; 12. History of acute or chronic pancreatitis, or related diseases that are most common cause of acute pancreatitis (such as recurrent cholelithiasis, etc.); 13. Combined use of drugs that affect glucose metabolism, such as glucocorticoids; 14. Combined use of Chinese herbal medicine with the effect of regulating blood glucose within 3 months; 15. Those who have serious diseases and may be in danger of life during treatment and follow-up; 16. Mental and neurological disorders, unable to correctly express their wishes; 17. Alcoholics and drug abusers and addicts; 18. Women of childbearing age are pregnant, breastfeeding, have pregnancy intentions or have a positive pregnancy test (urine HCG or blood HCG), and should not take effective contraceptive measures during the trial (effective contraceptive measures include sterilization, intrauterine device, oral contraceptive or diaphragm method prescribed by local law); 19. Patients who have participated in clinical trials of other drugs or medical devices in the past 3 months; 20. Patients with other diseases that the researchers believe will not be able to evaluate or are unlikely to complete the expected course of treatment and follow-up.

Study Design


Intervention

Device:
Hydrogen generator
Patient inhales hydrogen gas for 2 hours per day in the flow rate of 2L/min via nasal cannula by applying hydrogen generator (HZS-2700A, Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks.
Analogue machine
Patient inhales normal air for 2 hours per day in the flow rate of 2L/min via nasal cannula with analogue machine for 12 weeks. This machine has the same appearance as the hydrogen generator.

Locations

Country Name City State
China Qingdao Traditional Chinese Medicine Hospital Qingdao Shandong

Sponsors (2)

Lead Sponsor Collaborator
Qingdao University Qingdao Hiser Medical Group

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in glycosylated hemoglobin (HbA1c) The change in HbA1c from baseline to Week 12 in hydrogen inhalation group compared to Placebo. Baseline and Week 12
Secondary Change in fasting plasma glucose (FPG) The change in FPG from baseline to Week 12 in hydrogen inhalation group compared to Placebo. Baseline and Week 12
Secondary Change in 2h-postprandial plasma glucose (2h-PPG) The change in 2h-PPG from baseline to Week 12 in hydrogen inhalation group compared to Placebo. Baseline and Week 12
Secondary Patients with HbA1c <7.0% Percentage of patients reaching HbA1c <7% at Week 12 At Week 12
Secondary Patients with HbA1c <6.5% Percentage of patients reaching HbA1c <6.5% at Week 12 At Week 12
Secondary Change in fasting plasma insulin The change in fasting plasma insulin from baseline to Week 12 in hydrogen inhalation group compared to Placebo. Baseline and Week 12
Secondary Change in insulin sensitivity and beta cell function assessed by the homeostatic model assessment (HOMA) The change in HOMA-IR and HOMA-ß from baseline to Week 12 in hydrogen inhalation group compared to Placebo. Baseline and Week 12
Secondary Change in serum lipid profile The change in total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides from baseline to Week 12 in hydrogen inhalation group compared to Placebo. Baseline and Week 12
Secondary Change in waist circumference The change in waist circumference from baseline to Week 12 in hydrogen inhalation group compared to Placebo. Baseline and Week 12
Secondary Change in body weight The change in body weight from baseline to Week 12 in hydrogen inhalation group compared to Placebo. Baseline and Week 12
Secondary Change in body mass index (BMI) The change in BMI from baseline to Week 12 in hydrogen inhalation group compared to Placebo. Baseline and Week 12
Secondary Change in blood pressure The change in blood pressure from baseline to Week 12 in hydrogen inhalation group compared to Placebo. Baseline and Week 12
Secondary Change in oxidative stress index and inflammatory index Serum MDA and SOD, TNF-a, IL-6 quantifications were conducted using commercial kits from baseline to Week 12. Baseline and Week 12
Secondary Safety measurement The incidence rates of adverse events, clinical findings in the physical examination, vital signs, 12-lead electrocardiogram (ECG), clinical laboratory tests (hematology, blood biochemistry, and urinalysis) from baseline to Week 12. Baseline to Week 12
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A